Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00026520 · ClinicalTrials.gov registry record · Phase 2
Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma
A Phase 2 study, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00026520: Completed Phase 2 study, sponsored by SWOG Cancer Research Network.
NCT00026520 is a Phase 2 study that has completed, run by SWOG Cancer Research Network. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00026520, a Phase 2 study, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Interferon alfa may interfere with the growth of cancer cells and slow the growth of the tumor. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining interferon alfa with thalidomide may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining interferon alfa with thalidomide in treating patients who have stage IV melanoma.
Interventions
- BIOLOGICAL recombinant interferon alfa
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-11 |
| Est. Completion | 2006-04 |
| Phase | Phase 2 |
What the finished NCT00026520 record still lists
NCT00026520 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which recombinant interferon alfa is the first listed.
NCT00026520 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00026520 about?
NCT00026520 is a clinical study titled "Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma". RATIONALE: Interferon alfa may interfere with the growth of cancer cells and slow the growth of the tumor. Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. Combining interferon alfa with thalidomide may kill more tumor cells. PURPOSE: Phase II trial to study the effect...
What is the current status of trial NCT00026520?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-11. Estimated completion is 2006-04.
What interventions are being tested in trial NCT00026520?
The interventions under investigation include: recombinant interferon alfa (BIOLOGICAL), thalidomide (DRUG).
Who is sponsoring clinical trial NCT00026520?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia